Baxter International obtains antitrust clearance from FTC to sell injectable pharmaceuticals business to Hikma
Clients Baxter International Inc.
Jones Day represented Baxter International Inc. as antitrust counsel in connection with the sale of Baxter's injectable pharmaceuticals business to Hikma Pharmaceuticals PLC. Baxter's generic injectable products in vials and ampoules are sold primarily in the United States, and include chronic pain, anti-infective, and anti-emetic products. The Federal Trade Commission cleared the transaction following a comprehensive investigation and entry of a consent agreement with Hikma.